Osimertinib (Tagrisso) in combination with pemetrexed and platinum-based chemotherapy will shortly be assessed by the Scottish Medicines Consortium (SMC) for use in NHS Scotland
The indication this medicine will be assessed under is for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
We have been invited to provide a Patient Group Submission for the indications of this medicine, and are therefore trying to gather some patient’s experience quotes in support for this proposed treatment; you do not have to live in Scotland to comment and it would be extremely helpful to know the following:
What is your experience of living with EGFR positive lung cancer and how does this affect your quality of life.
What was your experience of Osimertinib (Tagrisso)/ Did you have any side effects and were they managed well.
How did being on Osimertinib (Tagrisso) affect your quality of life?
What has been your experience of treatment options with EGFR positive NSCLC?
If you are happy to comment on any of the questions, please get in touch, no personal details are needed but discussing it with you will help us put together the document on behalf of patients.
Please either comment below, private message or email ann.doran@roycastle.org, alternatively, you can phone the Roy Castle Ask the Nurse service on 0800 358 7200 Monday to Thursday 0900-1700 and Friday 0900-1600
All comments are welcome, so please do get in touch.
Thank you in advance.
Ann Doran
The Roy Castle Lung Cancer Foundation
small cell lung cancer
Small cell lung cancer
Do you have views on surgery?
Gone But Not Forgotten
Positive or helpful quotes need for Radiotherapy, Chemotherapy and Targeted Therapies for lung cancer booklets
